| |
Events - Third Meeting, 10-12 February 2000
The TACD met for the third time in Washington DC. Attending were leaders of all the major consumer organisations from both sides of the Atlantic and senior officials involved
with consumer and trade policy from the EU and the US.
The US Secretary of Agriculture Dan Glickman, EU Commissioner for Health and Consumer Protection, David Byrne and Rhoda Karpatkin, President of Consumers Union
of US, gave a keynote speech at the opening session. Congressman David Bonior, the Deputy US Trade Representative Sue Esserman; US Federal Trade Commissioner Mozelle
Thompson, the Ambassador of Portugal to the US Joao Rocha Paris; US Under Secretary of State Alan Larson, John Richardson, Deputy Head of the
EC Delegation to the US and Mauro Petriccione, Head of Unit at the EC's DG Relex also addressed the TACD conference
Jean Anne Fox, Director of Consumer Protection at the Consumer Federation of America; Joan Claybrook, President of Public
Citizen and Jim Murray, Director of the European Consumers Organisation spoke on the state of the transatlantic consumer movement.
Sheila McKechnie, Director of the UK Consumers Association spoke on the future of globalisation.
The TACD working groups have agreed a series of resolutions on:
Electronic commerce: Merger
of America Online and Time Warner and Privacy Protection; Junk
Email;
Linking; ICANN;
Jurisdiction
on Cross Border Consumer Contracts; Alternative
Dispute Resolution; Safe
Harbor; E-commerce
and Children
Food: Risk Analysis; Misleading
Food Labelling; The Impact of the TBT and SPS Agreements on Food Labeling and Safety
Regulations; Health Claims; Organic
Food
Detailed Papers: Bovine Encephalopathy (BSE) and other Transmissable Spongiform
Encelopathies (TSEs), Risk Analysis, Role
of "Science" and "Other Factors" in Risk Analysis, Consumers' concerns about Biotechnology
and Genetically Modified Organisms
Trade: Ethical labelling, Principles
for Harmonisation, Vehicle Safety Concerns, ecolabelling
Health Care and Intellectual Property: Access to Medecines in Developing Countries,
Data Exclusivity and Health Registration Data; Early
Working of Patents and Research Exceptions; Transparency of Pharmaceutical Economics; Patents
on genetic Diagnosis
|